Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 227

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1905.

https://doi.org/10.1182/blood-2019-132035

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Fabio Guolo, MD, Paola Minetto, MD, Luana Fianchi, MD, Michela Rondoni, MD, Giulia Daghia, MD, Stefano D'Ardia, MD, Monica Morselli, MD, Crescenza Pasciolla, MD, Francesca Pavesi, MD, Barbara MD Scappini, Francesco Lanza, MD, Marco Gobbi, MD, Livio Pagano, MD, Felicetto Ferrara, MD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 1363.

https://doi.org/10.1182/blood-2019-131329

Published: 2019

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 2836.

https://doi.org/10.1182/blood-2019-122969

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Late Effects in Survivors of Infant Acute Lymphoblastic Leukemia from the 3 Consecutive Japanese Nationwide Clinical Trials

Yuki Aoki, Akira Hayakawa, MD PhD, Kazutoshi Koike, MD PhD, Hisamichi Tauchi, MD PhD, Eiichi Ishii, MD PhD, Katsuyoshi Koh, MD, Takako Miyamura, MD PhD, Yasushi Ishida, MD PhD, Akiko Kada, MPH, Akiko M Saito, MD PhD, Atsushi Manabe, MD PhD, Keizo Horibe, MD PhD, Shuki Mizutani, MD PhD, Miho Maeda, MD, Daisuke Tomizawa, MD PhD

Blood (2019) 134 (Supplement_1): 4559.

https://doi.org/10.1182/blood-2019-123881

Published: 2019

Journal Articles

Patient Perception on Health Care Delivery for Sickle Cell Disease and Opportunities for Quality Improvement

Ofelia A. Alvarez, MD, Sandra Echenique, Hector Rodriguez-Cortes, MD, Thomas J. Harrington, MD, E. Leila Jerome Clay, MD MCTS, FAAP, Vandy Black, MDMSc, Mary Murph, Christopher Wells, Ifeyinwa (ify) Osunkwo, MDMPH

Blood (2019) 134 (Supplement_1): 5862.

https://doi.org/10.1182/blood-2019-123215

Published: 2019

Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3916.

https://doi.org/10.1182/blood-2019-124034

Published: 2019

Journal Articles

Impact of a Standardized Hydroxyurea Dose Regimen for Extreme Thrombocytosis in Children after Pancreatectomy with Islet Autotransplantation

Alexander A Boucher, MD, Todd M. Jenkins, PhD MPH, Lori Luchtman-Jones, MD, Joseph S. Palumbo, MD, Tom K Lin, MD, Maisam Abu-El-Haija, MD, Jaimie D Nathan, MD

Blood (2018) 132 (Supplement 1): 2529.

https://doi.org/10.1182/blood-2018-99-117205

Published: 2018

Journal Articles

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Jorge E. Cortes, MD, Cristina Papayannidis, Catriona Jamieson, MD PhD, Gary J. Schiller, MD, Anna Candoni, MD, Brian Leber, MD, Claudia D. Baldus, MD, José A. Pérez-Simón, MD PhD, Weidong Wendy Ma, Corrado Gallo Stampino, Ashleigh O'Connell, Mirjana Zeremski, MD, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2018-99-110934

Published: 2018

Journal Articles

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Norah Crossnohere, MPH, Daniel R. Richardson, MD MA, B. Douglas Smith, MD, Crystal Reinhart, Bernadette O'Donoghue, Susan Love, MD MBA, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2018-99-116931

Published: 2018

Journal Articles

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Karl W. Staser, MD PhD, Matthew L. Cooper, PhD, Jaebok Choi, PhD, Anand Chukka, Kidist Ashami, BA, Jessica Niswonger, Jaehan Park, Byung Ha Lee, PhD, Shunqiang Li, PhD, Amanda F Cashen, MD, Amy Musiek, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 340.

https://doi.org/10.1182/blood-2018-99-119375

Published: 2018

Journal Articles

Efficacy of Early Convert to Dasatinib in Chronic Myeloid Leukemia Patients Who Inresponse or Intolerance to Imatinib

Liu Liang, Na Xu, PhD, Xuan Zhou, PhD, Huang JiXian, Chen Chen, Lin Tong, Wu wan-Er, Changxin Yin, Qifa Liu, MD, Liu Xiaoli, MD

Blood (2018) 132 (Supplement 1): 5430.

https://doi.org/10.1182/blood-2018-99-114120

Published: 2018

Journal Articles

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Stefan Klaus Barta, MD MRCP, MS, Noah Kornblum, MD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Elizabeth Handorf, Joseph Sparano, MD, Richard Piekarz, MD PhD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2018-99-116991

Published: 2018

Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD

Blood (2018) 132 (Supplement 1): 5332.

https://doi.org/10.1182/blood-2018-99-110585

Published: 2018

Journal Articles

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Blood (2018) 132 (Supplement 1): 589.

https://doi.org/10.1182/blood-2018-99-110471

Published: 2018

Journal Articles

Experimental Modeling of Acute- and Chronic-GvHD By Xenotransplanting Human Donor PBMCs or Cord Blood CD34 + Cells (HSC) into NSG Mice

Ann E Lin, PhD, Sonia Reyes, Xiaoyu An, Sonia Reyes, Wenqing Yang, PhD, Derron Yu, Duan Dan, PhD, Henry Li, PhD

Blood (2018) 132 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2018-99-115462

Published: 2018

Journal Articles

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

Fangxin Hong, PhD, Gita Thanarajasingam, MD, Stephen M. Ansell, MD PhD, Richard F Ambinder, MD, Jonathon B. Cohen, MDMS, Michael Robertson, MD, Kevin A. David, MD, Ranjana H Advani, MD, Timothy S. Fenske, MD, Stefan Klaus Barta, MDMRCP,MS, Neil Palmisiano, MD, Jakub Svoboda, MD, David Morgan, MD, Reem Karmali, MD, Thomas E. Witzig, MD, Amylou C. Dueck, PhD, Paul Novotny, Brad S Kahl, MD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 623.

https://doi.org/10.1182/blood-2018-99-119372

Published: 2018

Journal Articles

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)

Ridhi Gupta, MD, Abdulwahab Albabtain, MD, Sally Arai, MD, Bernice Kwong, MD, Wen-Kai Weng, MD PhD

Blood (2018) 132 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2018-99-113915

Published: 2018

NARROW

Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Late Effects in Survivors of Infant Acute Lymphoblastic Leukemia from the 3 Consecutive Japanese Nationwide Clinical Trials

Patient Perception on Health Care Delivery for Sickle Cell Disease and Opportunities for Quality Improvement

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Impact of a Standardized Hydroxyurea Dose Regimen for Extreme Thrombocytosis in Children after Pancreatectomy with Islet Autotransplantation

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Efficacy of Early Convert to Dasatinib in Chronic Myeloid Leukemia Patients Who Inresponse or Intolerance to Imatinib

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Experimental Modeling of Acute- and Chronic-GvHD By Xenotransplanting Human Donor PBMCs or Cord Blood CD34 + Cells (HSC) into NSG Mice

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only